Cephalon snags $30M option on BioAssets

Cephalon has agreed to pay $30 million for an option to buy Wellesley, MA-based BioAssets Development Corp., which is pursuing new TNF inhibitors for sciatic pain in patients with intervertebral disk herniation and other spinal disorders. Provided Cephalon follows through on the option, it will make a follow-up payment and provide unspecified regulatory and sales milestones.

"BioAssets offers an estate of intellectual property and scientific expertise that will allow us to evaluate our own domain antibody tumor necrosis factor inhibitor, CEP-37247 (formerly known as ART-621), for the treatment of sciatica," said Frank Baldino, Jr., Ph.D. chairman and CEO of Cephalon. "Combining these two innovations helps fulfill our strategy to address unmet patient needs, while focusing on specialty physicians." 

- check out the release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.